Prognostic significance of intratumoral and peritumoral lymphatic density and blood vessel density in invasive breast carcinomas

American Journal of Clinical Pathology

Volumn 129, Issue 4, 2008, Pages 578-586

  El Gohary, Yasser M ^a   Metwally, Ghada ^b   Saad, Reda S ^c   Robinson, Morton J ^a   Mesko, Thomas ^a   Poppiti, Robert J ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b Ain Shams University Hospital   (Egypt)

^c ALLEGHENY GENERAL HOSPITAL   (United States)

Author keywords

Blood; Density; Invasive breast carcinoma; Lymphatics; Microvessels

Indexed keywords

CD31 ANTIGEN; MONOCLONAL ANTIBODY D2-40; MONOCLONAL ANTIBODY; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD VESSEL; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPH VESSEL; MICROVASCULATURE; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PRIORITY JOURNAL; PROGNOSIS; ADENOCARCINOMA; BREAST; BREAST TUMOR; CANCER INVASION; CHEMISTRY; ENZYME IMMUNOASSAY; METASTASIS; MICROCIRCULATION; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL RATE; VASCULARIZATION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD31; ANTIGENS, NEOPLASM; BREAST; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC VESSELS; MICROCIRCULATION; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 42949089094     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/2HGNJ1GU57JMBJAQ     Document Type: Article

References (47)

1. Folkman J, Shing Y. Angiogenesis. J Biol Chem. 1992;267: 10931-10934.
2. Folkman J. What is the evidence that tumors are angiogenesis dependent [editorial]? J Natl Cancer Inst. 1990;82:4-6.
3. Saad RS, Liu YL, Nathan G, et al. Endoglin (CD105) and vascular endothelial growth factor (VEGF) as prognostic markers in colorectal cancer. Mod Pathol. 2004;17:197-203.
4. El-Gohary YM, Silverman JF, Olson PR, et al. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma. Am J Clin Pathol. 2007;127:572-579.
5. Sleeman JP, Krishnan J, Kirkin V, et al. Markers for the lymphatic endothelium: in search of the holy grail? Microsc Res Tech. 2001;55:61-69.
6. Lymboussaki A, Partanen TA, Olofsson B, et al. Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors. Am J Pathol. 1998;153:395-403.
7. Nathanson SD. Insights into the mechanisms of lymph node metastasis. Cancer. 2003;98:413-423.
8. Locopo N, Fanelli M, Gasparini G. Clinical significance of angiogenic factors in breast cancer. Breast Cancer Res Treat. 1998;52:159-173.
9. Folkman J. Angiogenesis and angiogenesis inhibition: an overview. EXS. 1997;79:1-8.
10. Beasley NJ, Prevo R, Banerji S, et al. Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer. Cancer Res. 2002;62:1315-1320.
11. Maula SM, Luukkaa M, Grenman R, et al. Intratumoral lymphatics are essential for the metastatic spread and prognosis in squamous cell carcinomas of the head and neck region. Cancer Res. 2003;63:1920-1926.
12. Hall FT, Freeman JL, Asa SL, et al. Intratumoral lymphatics and lymph node metastasis in papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg. 2003;129:716-719.
13. Karpanen T, Egeblad M, Karkkainen MJ, et al. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res. 2001;61:1786-1790.
14. Mandriota SJ, Jussila L, Jeltsch M, et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumor metastasis. EMBO J. 2001;20:672-682.
15. Stacker SA, Caesar C, Baldwin ME, et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med. 2001;7:186-191.
16. Skobe M, Hawighorst T, Jackson DG, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med. 2001;7:192-198.
17. Karpanen T, Alitalo K. Lymphatic vessels as targets of tumor therapy? J Exp Med. 2001;194:F37-F42.
18. Fisher B, Bauer M, Wickerham DL, et al. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer: an NSABP update. Cancer. 1983;52:1551-1557.
19. Gombos Z, Xu X, Chu CS, et al. Peritumoral lymphatic vessel density and vascular endothelial growth factor C expression in early stage squamous cell carcinoma of the uterine cervix. Clin Cancer Res. 2005;11:8364-8371.
20. Breiteneder-Geleff S, Soleiman A, Kowalski H, et al. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol. 1999;154:385-394.
21. Van der Auwera I, van Laere SJ, van den Eynden GG, et al. Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Clin Cancer Res. 2004;10:7965-7971.
22. Marks A, Sutherland DR, Bailey D, et al. Characterization and distribution of an oncofetal antigen (M2A antigen) expressed on testicular germ cell tumours. Br J Cancer. 1999;80:569-578.
23. Kahn HJ, Bailey D, Marks A. Monoclonal antibody, D2-40, a new marker of lymphatic endothelium, reacts with Kaposi's sarcoma and a subset of angiosarcomas. Mod Pathol. 2002;15: 434-440.
24. Kahn HJ, Marks A. A new monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors. Lab Invest. 2002;82:1255-1257.
25. Greene FL, Page DL, Fleming ID, et al; for the American Joint Committee on Cancer, eds. Cancer Staging Manual. 6th ed. New York, NY: Springer; 2002.
26. Saad RS, Kordunsky L, Denning KL, et al. Lymphatic microvessel density as prognostic marker in colorectal carcinoma. Mod Pathol. 2006;19:1317-1323.
27. Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat. 1995;36:169-180.
28. Thames HD, Buchholz TA, Smith CD. Frequency of first metastatic events in breast cancer: implications for sequencing of systemic and local-regional treatment. J Clin Oncol. 1999;17:2649-2658.
29. Fogt F, Zimmerman RL, Ross HM, et al. Identification of lymphatic vessels in malignant, adenomatous and normal colonic mucosa using the novel immunostain D2-40. Oncol Rep. 2004;11:47-50.
30. Jackson DG. The lymphatics revisited: new perspectives from the hyaluronan receptor LYVE-1. Trends Cardiovasc Med. 2003;13:1-7.
31. Partanen TA, Alitalo K, Miettinen M. Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors. Cancer. 1999;86:2406-2412.
32. Valtola R, Salven P, Heikkila P, et al. VEGF-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol. 1999;154:1381-1390.
33. Mouta Carreira C, Nasser SM, di Tomaso E, et al. LYVE-1 is not restricted to lymph vessels: expression in normal liver blood sinusoids and down-regulation in human liver cancer and cirrhosis. Cancer Res. 2001;61:8079-8084.
34. Nakamura Y, Yasuoka H, Tsujimoto M, et al. Flt-4-positive vessel density correlates with vascular endothelial growth factor-D expression, nodal status, and prognosis in breast cancer. Clin Cancer Res. 2003;9:5313-5317.
35. Schoppmann SF, Bayer G, Aumayr K, et al. Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg. 2004;240:306-312.
36. Birner P, Schindl M, Obermair A, et al. Lymphatic microvessel density as a novel prognostic factor in early stage invasive cervical cancer. Int J Cancer. 2001;95:29-33.
37. Choi WW, Lewis MM, Lawson D, et al. Angiogenic and lymphangiogenic microvessel density in breast carcinoma: correlation with clinicopathologic parameters and VEGF-family gene expression. Mod Pathol. 2005;18:143-152.
38. Uzzan B, Nicolas P, Cucherat M, et al. Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res. 2004;64:2941-2955.
39. Padera TP, Kadambi A, di Tomoso E, et al. Lymphatic metastasis in the absence of functional intratumoral lymphatics. Science. 2002;296:1883-1886.
40. Clarijs R, Ruiter DJ, de Waal RM. Lymphangiogenesis in malignant tumors: does it occur? J Pathol. 2001;193:143-146.
41. Williams CS, Leek RD, Robson AM, et al. Absence of lymphangiogenesis and intratumoral lymph vessels in human metastatic breast cancer. J Pathol. 2003;200:195-206.
42. Agarwal B, Saxena R, Morimiya A, et al. Lymphangiogenesis does not occur in breast cancer. Am J Surg Pathol. 2005;29:1449-1455.
43. Vleugel MM, Bos R, van der Groep P, et al. Lack of lymphangiogenesis during breast carcinogenesis. J Clin Pathol. 2004;57:746-751.
44. Sipos B, Klapper W, Kruse ML, et al. Expression of lymphangiogenic factors and evidence of intratumoral lymphangiogenesis in pancreatic endocrine tumors. Am J Pathol. 2004;165:1187-1197.
45. Bono P, Wasenius VM, Heikkila P, et al. High LYVE-1 positive lymphatic vessel numbers are associated with poor outcome in breast cancer. Clin Cancer Res. 2004;10:7144-7149.
46. Arnaout-Alkarain A, Kahn HJ, Narod SA, et al. Significance of lymph vessel invasion identified by the endothelial lymphatic marker D2-40 in node negative breast cancer. Mod Pathol. 2007;20:183-191.
47. Tsutsui S, Kume M, Era S. Prognostic value of microvessel density in invasive ductal carcinoma of the breast. Breast Cancer. 2003;10:312-319.